Article Sidebar

PDF
Date Published: 28/08/2025
Abstract Views: 18
Views PDF: 9
DOI: https://doi.org/10.56535/jmpm.v50i6.1276
Issue
Vol. 50 No. 6 (2025): TẠP CHÍ Y DƯỢC HỌC QUÂN SỰ SỐ 6 - 2025
Section
Articles
How to Cite
Dương, T. L., Hồ , V. H., Nguyễn, K. V., Hồ, H. T., & Nguyễn, V. B. (2025). RESEARCH ON THE CHARACTERISTICS OF SEPT9 GEN METHYLATION IN SERUM BEFORE AND AFTER SURGERY IN STAGE III COLORECTAL CANCER. Journal of Military Pharmaco-medicine, 50(6), 100-108. https://doi.org/10.56535/jmpm.v50i6.1276

RESEARCH ON THE CHARACTERISTICS OF SEPT9 GEN METHYLATION IN SERUM BEFORE AND AFTER SURGERY IN STAGE III COLORECTAL CANCER

Thuỳ Linh Dương1, , Viết Hoành Hồ 1, Khánh Vân Nguyễn2, Hữu Thọ Hồ3, Văn Ba Nguyễn4
1 Trung tâm Ung bướu, Bệnh viện Quân y 103, Học viện Quân y
2 Cục Quân y, Tổng cục Hậu cần Kỹ thuật
3 Viện Nghiên cứu Y Dược học Quân sự, Học viện Quân y
4 Bệnh viện Quân y 175

Main Article Content

Abstract

Objective: To study the characteristics of SEPT9 gene methylation (mSEPT9) in peripheral blood before and after radical surgery in patients with stage III colorectal cancer (CRC). Methods: A cross-sectional descriptive study, with  follow-up of 50 stage III CRC patients treated at Military Hospital 103 and K Hospital from January 2021 to December 2024. Results: The percentage of positive mSEPT9 in plasma after surgery was 34% (17/50), significantly reduced compared to 84% (42/50) before surgery. ROC curve analysis showed that the value of distinguishing the progression status when combining positive mSEPT9 before and after surgery was good (AUC=0,755, p<0,05). Patients with positive mSEPT9 after surgery higher risk of progression compared to those with negative mSEPT9 after surgery (OR=7, p<0,05). Multivariate analysis indicated that mSEPT9 after surgery (HR: 10,738, p<0,05) is an independent predictive factor for significantly shorter PFS in stage III CRC patients with positive mSEPT9 after surgery. Conclusion: mSEPT9 has prognostic value and is useful for monitoring progression after radical surgery in stage III CRC patients.

Article Details

Keywords

colorectal cancer, stage III, methylation gen SEPT9, radical surgery

References

1. Bray Freddie, et al. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Global Cancer Statistics. 2022; 74(3):229-263.
2. Nors Jesper, et al. Incidence of recurrence and time to recurrence in stage I to III colorectal cancer: A nationwide danish cohort study. 2024; 10(1):54-62.
3. Gao Zhaoya, et al. Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancer. Journal of Translational Medicine. 2023; 21(1):63.
4. Lofton-Day Catherine, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clinical Chemistry. 2008; 54(2):414-423.
5. Yuan Zhen, et al. Circulating methylated SEPT9 DNA analyses to predict recurrence risk and adjuvant chemotherapy benefit in stage II to III colorectal cancer. Medical Science Monitor. 2022; 28:e937757.
6. Gao Hua, et al. The value of serum methylated septin 9 and carcinoembryonic antigen in efficacy evaluation and follow-up monitoring of colorectal cancer. Annali ltaliani di Chirurgia. 2023; 94(4):384-391.
7. Li Rong, et al. A study of the clinical significance of mSEPT9 in monitoring recurrence and prognosis in patients with surgically treated colorectal cancer. Plos one. 2024; 19(10):e0312676.
8. Krokowski Sina, et al. Bacterial cell division is recognized by the septin cytoskeleton for restriction by autophagy. Autophagy. 2019; 15(5):937-939.